Kenneth Carl Anderson - 18 Jun 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
18 Jun 2025
Transactions value $
$0
Form type
4
Filing time
20 Jun 2025, 16:11:29 UTC
Previous filing
03 Apr 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Anderson Kenneth Carl Director C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN /s/ Jolie M. Siegel, Attorney-in-Fact 20 Jun 2025 0001824862

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +35.5K $0.00 35.5K 18 Jun 2025 Common Stock 35.5K $1.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.